EGFR and breast cancer: An epidermal growth factor receptor (EGFR)-binding Fn3, previously engineered by yeast surface display, known as Clone A (CA), satisfied both of the above criteria; EGFR has been targeted in treating colon, neck, and breast cancer [13] and CA binds EGFR with single-digit nanomolar affinity [11].